MBX Biosciences develops peptide-based drug candidates for endocrine and metabolic disorders, including a lead treatment for a rare hormone disorder. MBX reports earnings on Thu, Nov 5, 2026. Analyst consensus is Strong Buy, based on the latest ratings from 4 firms (4 buy, 0 hold, 0 sell). In the past 30 days there were 2 dark pool prints.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 12 | Stifel | Maintained | Buy | |
| Oct 2 | Guggenheim | Maintained | Buy | |
| Aug 21 | JP Morgan | Reinstated | Buy | |
| Aug 10 | Truist Securities | Maintained | Buy | |
| Jul 29 | Mizuho | Maintained | Buy |
Whale Options Flow
90DNo whale options trades in MBX in the last 90 days.
Dark Pool
30DAI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether MBX is in one of them and how their past MBX trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered MBX in an article yet. Here's the latest on the wider market.
About MBX Biosciences
MBX Biosciences is a biopharmaceutical company based in Carmel, Indiana, that develops peptide medicines for hormone and metabolic conditions. Its candidates are built on a proprietary platform designed to give peptides longer action and steadier levels in the body, so they can be taken less often. The lead candidate targets chronic hypoparathyroidism, a rare hormone disorder. The company is also developing treatments for obesity and for low blood sugar after weight loss surgery. Its candidates are still in development, and its intended users are patients with these conditions.
- Headquarters
- Carmel, IN